Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair

Key Points

• William Blair initiated coverage of Enliven Therapeutics with an “outperform” rating. The stock has a “Moderate Buy” consensus, with eight Buy ratings and one Sell rating and an average price target of $75.
• Enliven shares opened at $59.53, near their 52-week high of $62.32, while the company reported quarterly EPS of negative $0.49, missing estimates of negative $0.39.
• Insiders sold 190,831 shares worth approximately $11.0 million during the last quarter, while institutional investors own 95.08% of the company; Enliven is developing targeted protein-degradation therapies for cancer.

Stock analysts at William Blair started coverage on shares of Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an "outperform" rating on the stock.

Several other brokerages also recently issued reports on ELVN. Barclays began coverage on Enliven Therapeutics in a research note on Tuesday. They issued an "overweight" rating and a $78.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Mizuho upped their price target on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a research note on Tuesday. Stifel Nicolaus boosted their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, JonesTrading raised their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $75.00.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $59.53 on Tuesday. The company has a 50-day moving average of $51.42 and a two-hundred day moving average of $41.13. The stock has a market cap of $4.36 billion, a price-to-earnings ratio of -35.65 and a beta of 0.27. Enliven Therapeutics has a one year low of $14.78 and a one year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Analysts anticipate that Enliven Therapeutics will post -1.67 earnings per share for the current year.

Insider Transactions at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of the company's stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares in the company, valued at approximately $2,114,723.16. This represents a 19.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the transaction, the director directly owned 87,373 shares in the company, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 190,831 shares of company stock worth $10,991,723. 3.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors have recently modified their holdings of the company. Commodore Capital LP raised its holdings in Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock worth $94,138,000 after acquiring an additional 17,809 shares during the period. BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics in the second quarter valued at about $221,255,000. Vestal Point Capital LP grew its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc lifted its position in shares of Enliven Therapeutics by 13.5% during the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company's stock worth $54,111,000 after purchasing an additional 418,673 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company's stock valued at $52,260,000 after purchasing an additional 142,378 shares during the period. Institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source